Instem Share Discussion Threads

[p1nkfish] 08/1/2019 16:23

Trading statement about 16th January last year.
We could do with a snapshot of where the company now stands.

[mw8156] 21/11/2018 12:08

wonder if the recent price fall is sentiment or whether they are lining up the 'transformational' acquisition? if the latter, have to hope they allow small holders the option participate in any associated fund-raising.

[geraldus] 26/9/2018 16:17

I was wondering if transformational opportunities would also include a large discounted cash call.

[mw8156] 26/9/2018 14:07

having reread the statement, it keeps referring to acquisition targets, possibly including transformational opportunities, rather than being acquired though I suppose the latter is always a possibility that they would not know about til an offer is made.

[mw8156] 24/9/2018 12:50

many thanks for that clarification, 2niffy,

[2niffy] 24/9/2018 12:43

Results fine, good to see positive cash flow but slightly disappointed not to see more organic growth but given order intake should flow through to second half.Statement suggests 'continued complimentary acquisitions possible transformational opportunities 'Transformational opportunities not necessarily same as acquisition. Private equity would be interested in facilitating consolidation.

[mw8156] 24/9/2018 11:36

results look ok, just a little concerned about the prospect for a 'transformational acquisition' hope they have the management capability if they undertake such a move.

[modform] 20/9/2018 17:32

This is so illiquid, around 6000 shares bought, lifts the share price up by 8%

[p1nkfish] 20/9/2018 12:49

I can't see anything but demand increase as likely.

[modform] 20/9/2018 12:33

Starting to rise in anticipation of results on Monday All depends on the uptake of SEND

[p1nkfish] 04/9/2018 12:56

Expecting acquisition targets are being sifted too. They will probably want to bulk up a little.

[wjccghcc] 04/9/2018 11:38

I think it's too lightly traded to make the chart relevant. It only takes 3000 shares to move it 10p either direction. Results should be in 3 weeks or so which will make interesting reading. As 2niffy says, the increase in cash vs what's usually a seasonal outflow is very positive. SEND is at an early stage in it's ramp up. I think this year will be encouraging but that next year is when things will really start moving.

[p1nkfish] 04/9/2018 11:31

I suspect the bunch below are reducing their holding.

INNOVALTO 2015 fund
FORTUNE EUROPE 2014 fund
OBJECTIF EUROPE fund
FORTUNE EUROPE 2015 fund

At the same time it looks like a cup and handle is forming but I'm not 100% sure. If it is then I have £4.50 price target in mind.

Anyone care to chip in.

[2niffy] 23/7/2018 11:59

Very encouraged with regards to balance sheet. Generated cash of 600k in the first half and that was after final payment of 200k in respect of deferred acquisition. Seasonal negative cash flow of 1.5m for last couple of years.Cash is the only true measure of profitability.Could also benefit from reduced cash contributions been made towards pension fund. Triennial pension fund review due shortly. Deficit much reduced and bond yields moving up.

[slopsjon2] 23/7/2018 07:16

Trading Update
Results in-line with management expectations
SEND contract value in H1 2018 exceeds that for the entire FY2017
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces a trading update for the six months to 30 June 2018 (the "Period").

Financial Highlights
Trading for the Period was in-line with management expectations. Net cash as at 30 June 2018 was GBP3.7m (30 June 2017; GBP1.2m).
Operational Highlights
There were positive contributions in most areas, with several significant new client wins in addition to existing customers extending and expanding their adoption of Instem's products and services.
Investment in Instem's early phase clinical product, Alphadas, was increased with a focus on current client needs and recognising that the enhancements will have wider market appeal going forward.

Importantly, the business continued to expand its SaaS delivery model for accessing its solutions via the Instem Cloud with both Provantis(R) and Samarind RMS being deployed via Software-as-a-Service by additional multinational corporations.

SEND Market Update
The Regulatory Solutions business performed particularly strongly during the period following the latest FDA mandate of the Standard for the Exchange of Non-clinical Data ("SEND").

Increasing Number of Contract Wins Orders for the Company's SEND software solutions and technology-enabled SEND out-sourced services over the period have increased year-on-year with 103 orders won during the six-month period ended 30 June 2018, compared to 47 and 65 for the first and second six-month periods of 2017 respectively. Importantly, more SEND out-sourced services deals were closed in the first half of 2018 than for the entire 2017 financial year. These contract wins will increasingly impact overall Group revenues in H2 and beyond in line with recruitment of the necessary services personnel, which has been ongoing throughout 2018.

These new orders came from 50 unique clients during the period, compared with 32 for the equivalent period last year and the Company continues to win the overwhelming majority of all business quoted for.
All of Instem's study conversions are performed on a secure, hosted and validated SEND services platform, which is available and supported 24/7 utilising Instem's submit(TM) SEND software suite. This is the same submit(TM) software that is in production use at pharma and contract research organisations worldwide.

Increasing Contract Value
The total contracted value of SEND-related new business for the current period increased approximately 190% over the corresponding period last year with outsourced services orders particularly strong.

Increasing Pipeline
The Company continues to believe that this rapid growth has been largely driven by the IND ('Investigational New Drug') legislation from the FDA, which mandated that studies started after 17 December 2017 and included in IND regulatory submissions must use the electronic SEND format.
Future demand appears to be similarly robust and the Company has a strong SEND new business pipeline for both technology and service related sales, with both the number and value of SEND contracts expected to increase in the second half of 2018 and expected to be significantly ahead of last year.

Outlook
The further shift towards a SaaS based revenue model, combined with increasingly material recurring outsourced services revenue, will see a continued improvement of earnings visibility. This helps position the Company strongly to meet management's full year expectations.

Phil Reason, CEO of Instem plc, commented:
"The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year."

[p1nkfish] 23/7/2018 07:15

Growth is the order of the day. Good update. Steasybas she goes and good cash position increase.

[p1nkfish] 14/7/2018 06:56

Instem will breakthrough that double top of Sept 2016 and April 2018. About 330p and ideally by a few %.

[2niffy] 27/6/2018 10:37

On 6th June CEO stated that they expect to release a trading update at the end of the month. Let's hope that momentum in orders falls through to bottom line. Expect news regarding new facilities in India funded from a healthy balance sheet!

[p1nkfish] 06/6/2018 22:37

Around only 1,092,997 shares not in the hands of holders of 3%÷ or Directors. Only a matter of time.

[p1nkfish] 06/6/2018 18:41

Good news today. It will get through 330p in time, then upwards. In a pharma sweet spot.

[p1nkfish] 24/5/2018 08:18

17th May 2018 ARTEMIS VCT half Yearly statement:

"A strong balance sheet is, in our opinion, an invaluable resource for small companies allowing management teams the scope to invest when required and deal with any near term trading volatility. Instem plc is a good example. Additional investment, along with contract deferrals, were to blame for a difficult 2017 but having cash on the balance sheet allowed them to weather the storm and 2018 has started on a much brighter note. Fears of a profit warning were misplaced with a positive trading update well received in January alongside a large contract win. The company has, in recent years, successfully positioned itself as the leading expert in the field of electronic data submissions to the Food and Drug Administration ("FDA") in the US and this now looks likely to deliver the anticipated benefits marking a sharp reversal of fortunes for the group."

[p1nkfish] 12/4/2018 13:43

If they execute this is a keeper. Picks and shovels in bio, pharmaceutical, software. Whether a drug gains approval or not is not Instems problem so that risk is removed. Execution risk is #1 from my perspective. Aligning management to shareholder interests is key, Same everywhere really.

[jinxo777] 12/4/2018 13:18

I was expecting a pull back when we reached 300p but that didn't happen - I am not complaining though! Managed to free up some cash and bought another 4k shares over the last week or so. Very difficult to buy in size; if we get any decent news in the next month or so these will fly!! good luck all!

[p1nkfish] 11/4/2018 16:12

I do like a quiet PBB.

One day I'm expecting a similar sort of rise in UBI in which there is currently no interest.